Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

doi:10.1007/s00280-017-3323-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

Cancer chemotherapy and pharmacology - 1 Jul 2017

Sissung Tristan M, Peer Cody J, Korde Neha, Mailankody Sham, Kazandjian Dickran, Venzon David J, Landgren Ola, Figg William D

Abstract excerpt

The combination of carfilzomib, lenalidomide, and dexamethasone (CRd) has induced deep responses in patients with newly diagnosed multiple myeloma. While vascular endothelial growth factor (VEGF) pathway polymorphisms have been associated with clinical outcomes for antiangiogenesis agents, we explored associations between such polymorphisms and CRd clinical response. The VEGF-1498C>T (rs833061) and VEGFR2 V297I...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dexamethasone

Share to Lenalidomide

Share to Multiple Myeloma

Share to Oligopeptides

Share to Thalidomide

Share to Vascular Endothelial Growth Factor A

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Open in PubMed Open full text

Identifiers

PMID: 28488026
DOI: 10.1007/s00280-017-3323-8
PMCID: PMC6387687

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.PMID 28488026Read ↗

Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.Semantic proximity Read ↗

Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma.Semantic proximity Read ↗

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens.Semantic proximity Read ↗

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.Semantic proximity Read ↗

Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.Semantic proximity Read ↗

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.Semantic proximity Read ↗

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Semantic proximity Read ↗

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.